PlainRecalls
FDA Drug Low Class III Terminated

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Reported: April 12, 2023 Initiated: March 27, 2023 #D-0510-2023

Product Description

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Reason for Recall

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Details

Units Affected
3,772 cartons
Distribution
USA Nationwide
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19. Recalled by Teva Pharmaceuticals USA Inc. Units affected: 3,772 cartons.
Why was this product recalled?
Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 12, 2023. Severity: Low. Recall number: D-0510-2023.